Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12868851 | 0.81 | CA1 (0.36) | L3MBTL1CA1MLYCDBLM | |
| SCHEMBL16077733 | 0.79 | CA1 (0.34) | L3MBTL1CA1ALDH1A1TDP1MLYCD | |
| SCHEMBL14770977 | 0.79 | CES2 (0.50) | L3MBTL1CA1MLYCD | |
| SCHEMBL15423500 | 0.77 | ALDH1A1 (0.37) | L3MBTL1CA1ALDH1A1TDP1 | |
| SCHEMBL16448765 | 0.75 | ALDH1A1 (0.38) | ALDH1A1TDP1 | |
| Ammonia Solution, Strong SCHEMBL28258790 | 0.74 | CA1 (0.31) | L3MBTL1CA1 | |
| SCHEMBL1698105 | 0.73 | CA1 (0.37) | L3MBTL1CA1ALDH1A1TDP1BLM | |
| SCHEMBL15080398 | 0.73 | CA1 (0.37) | L3MBTL1CA1ALDH1A1TDP1BLM | |
| SCHEMBL810028 | 0.72 | — | — | |
| SCHEMBL16081349 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192756-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | Sage Therapeutics, LLC | 2023-06-22 | — | — | US | disclosed |
| US-20160022701-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS INC (US) | 2016-01-28 | — | — | US | disclosed |
| US-20150158903-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. (US) | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022701-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | CYP21A2, CYP24A1, HSD17B2 | L3MBTL1 3127/4885CA1 1639/4885ALDH1A1 1548/4885 |
| US-20230192756-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | CHRNB4, CHRNB3, MC2R | L3MBTL1 2071/4885CA1 1571/4885ALDH1A1 1160/4885 |
| US-20150158903-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | CHRNB4, CHRNB3, MC2R | L3MBTL1 2071/4885CA1 1571/4885ALDH1A1 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.